GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Updated November 7, 2026 | v7.4

Renal updates by clinical finding

Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.

Reset

Search all 1,215 records | Source cautions

No adjustment within stated limits

Caspofungin acetate (Cancidas), IV injection

Renal measure
Renal impairment categories as defined by the cited product label
Renal action or finding
Renal impairment does not require a caspofungin dose change. Hemodialysis does not necessitate supplemental dosing.
Limits and monitoring
Hepatic impairment and interacting medications can alter the regimen independently.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 42, posted Oct 14, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Cefixime (Suprax), oral capsule

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
Use the usual adult dose and interval at CrCl 60 mL/min or greater. Below that value use the table for the specified presentation and suspension concentration.
Limits and monitoring
Conventional hemodialysis and peritoneal dialysis remove little cefixime. Check the exact formulation when a reduced dose is needed.

Verify the current prescribing information for this presentation.

DailyMed SPL version 2, posted Dec 30, 2019 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Ceftaroline fosamil (Teflaro), adult IV infusion

Renal measure
Cockcroft-Gault CrCl, mL/min
Renal action or finding
Adult IV ceftaroline doses every 12 hours are 400 mg at CrCl above 30 through 50, 300 mg at 15 through 30, and 200 mg below 15 mL/min, including ESRD on HD. Administer after HD on dialysis days.
Limits and monitoring
The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 43, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Ceftazidime (Fortaz), IM or IV injection

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
Reduce maintenance dosing for impaired renal elimination. Select dose and interval using the adult renal table, the infection severity, and the organism's susceptibility.
Limits and monitoring
Excess exposure may cause encephalopathy, myoclonus or seizures. Verify the relevant dialysis schedule separately.

Verify the current prescribing information for this presentation.

DailyMed SPL version 9, posted Sep 13, 2019 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Ceftazidime (Tazicef), IM or IV injection

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
Adjust ceftazidime maintenance for impaired clearance. Match the schedule to kidney function, infection severity, and organism susceptibility.
Limits and monitoring
High concentrations during reduced urine output can cause neurologic toxicity. Verify the indication and dialysis modality.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 16, posted May 13, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Ceftobiprole medocaril sodium (Zevtera), IV injection

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
For adults use the IV label's renal table when CrCl is below 50 mL/min. Select dose and interval for the indication and phase of treatment; use the HD instructions on dialysis days.
Limits and monitoring
Pediatric adjustments use indexed eGFR and age-specific criteria. Confirm ceftobiprole medocaril sodium versus active ceftobiprole when reading doses.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 7, posted Nov 04, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

No adjustment within stated limits

Ceftriaxone (Ceftriaxone), adult IV premixed solution

Renal measure
Renal impairment categories as defined by the cited product label
Renal action or finding
For renal impairment alone, doses up to 2 g/day generally need no adjustment. Hemodialysis removes little ceftriaxone.
Limits and monitoring
Concomitant significant renal and hepatic dysfunction requires separate review. Monitor for neurologic toxicity, particularly with severe impairment.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 26, posted May 21, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Restriction or avoidance

Celecoxib (Celebrex), oral capsule

Renal measure
Renal impairment categories as defined by the cited product label
Renal action or finding
Severe renal insufficiency is a reason to avoid routine celecoxib treatment.
Limits and monitoring
Monitor renal function and volume status if clinical circumstances justify use.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 13, posted Dec 18, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Restriction or avoidance

Cidofovir (Vistide), IV injection

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Renal measure
Serum creatinine, CrCl and urine protein
Renal action or finding
Do not initiate IV cidofovir if baseline serum creatinine exceeds 1.5 mg/dL, calculated CrCl is 55 mL/min or less, or urine protein is at least 100 mg/dL (2+).
Limits and monitoring
Systemic IV use requires labeled saline hydration and probenecid. Reassess creatinine and urine protein before each dose.

Verify the current prescribing information for this presentation.

DailyMed SPL version 6, posted Sep 30, 2013 | Selected sections checked 2026-11-07. Independent clinical review pending.

Insufficient evidence

Clopidogrel (Plavix), oral tablet

Renal measure
Renal impairment categories as defined by the cited product label
Renal action or finding
Clinical experience is limited in moderate and severe renal impairment. The cited platelet-function data do not establish a renal replacement regimen.
Limits and monitoring
Choose therapy according to the cardiovascular indication and bleeding risk.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 5, posted Jun 11, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

No adjustment within stated limits

Cobimetinib (Cotellic), oral tablet

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
At CrCl 30-89 mL/min, population pharmacokinetics support usual cobimetinib dosing. A dose has not been established in severe impairment.
Limits and monitoring
Consider the entire oncology regimen and treatment-emergent toxicity.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 24, posted Sep 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Insufficient evidence

Colesevelam hydrochloride (Welchol), oral tablet

Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
The six cited diabetes trials included mild and moderate impairment but enrolled no patients with CrCl below 30 mL/min.
Limits and monitoring
This is a population evidence limit and supplies no severe-impairment dosing schedule.

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 3, posted Dec 04, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.

RX coverage and remaining workload | Previous 90-product roundup
Top